X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    New Delivery Path Brings To Light Efficacy of Immunotherapy

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    New Delivery Path Brings To Light Efficacy of Immunotherapy

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development Research & Development

Patient-focused Discoveries and Treatments

Yuvraj_pawp by Yuvraj_pawp
5th October 2015
in Research & Development

Alcon transforms eye care possibilities into therapeutic realities through the discovery and development of innovative eye care products and treatments.

Eye Care Products

Our global team of approximately 1,800 highly skilled individuals dedicated to R&D drive our efforts to relentlessly innovate and find solutions for current and future unmet needs in eye care. Consider the following statistics regarding the growing incidence of eye disease:

• 80% of all visual impairment can be prevented, treated or cured1
• 90% of people that are visually impaired live in developing countries2
• 1.8 million people suffer from age-related macular degeneration (AMD)3
• 67 million people worldwide are affected by glaucoma 4causing irreversible loss of vision if left untreated5

Research Areas and Product Development Focus

Alcon’s leadership and future growth is driven by breakthrough innovation. Our focus is to continue to build trusted partnerships with eye care professionals around the world, offering a diversified yet focused product portfolio that serves the full lifecycle of patient needs across eye diseases, vision conditions and refractive errors.

Filling the Pipeline

We create innovative eye care treatments and prioritize our work based on unmet medical needs and a strong scientific understanding of eye diseases and conditions. With a focused pipeline that aligns with our three business groups – Surgical, Pharmaceutical and Vision Care – we are able to focus on the discovery and identification of new eye care solutions and treatments for the future.

Alcon fills the R&D pipeline through in-house development, partnerships with leading institutions, acquisitions, andin-licensing. The strategy behind our pipeline is a precise scientific approach that helps us select and advance therapies specific to disease areas of the eye, and this determines which technologies will enter our R&D portfolio. Our pipeline strategy consists of three distinct, but connected parts:

First, the strategy is built around specific unmet medical needs within our four therapeutic areas:

• Glaucoma, Cataract & Refractive Error, Retina, and External Disease.
• Second, Alcon identifies the short-term and long-term response strategy to the unmet needs.
• Third, specific research targets are selected using a Proof of Concept approach.

Previous Post

Hillary Clinton Proposes $250 Monthly Cap on Prescription Drug Costs

Next Post

Eureka Therapeutics Inc. and Boehringer Ingelheim Announce a Collaboration to Identify Next Generation Antibodies for Cancer Treatment

Related Posts

Tumors Can Get Destroyed By Bacteria-Aid To Immune System
News

Tumors Can Get Destroyed By Bacteria-Aid To Immune System

16th March 2023
News

Researchers Develop Revolutionary Treatment In Bone Cancer

10th March 2023
News

T Cells Are Fruitful In Thwarting-Off Chronic Infections

10th March 2023
News

Randomness Drives Tumour Cells Response To Chemotherapy

10th March 2023
Featured

Animal Testing Could See An End With An Artificial Model

28th February 2023
Featured

Germany Rolls First CAR-T Push For Muscle Inflammation Cure

27th February 2023
Next Post

Eureka Therapeutics Inc. and Boehringer Ingelheim Announce a Collaboration to Identify Next Generation Antibodies for Cancer Treatment

Latest News

Drug Development

New Delivery Path Brings To Light Efficacy of Immunotherapy

1st April 2023
Cathay Cargo signs global airline partnership with Tower Cold Chain
Packaging & Logistic

Cathay Cargo signs global airline partnership with Tower Cold Chain

31st March 2023
Quotient Sciences completes integration of drug substance into Translational Pharmaceutics Platform
Facilities & Operation

£277m Funding Set To Benefit UK Life Sciences Manufacturing

31st March 2023
Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In